Evaluation of Cellular and Humoral Immune Responses of Piroxicam in Murine Model

Bashra Zahoor1, Aqeel Javeed1*, Naeem ur Rehman2, Ahmed Tokhi2, Zainab Ahmed2, Khadijeh Esmailpour4*, Muhammad Ashraf1, Jawad Nazir3 and Ahmad Hamdani D1

1Department of Pharmacology and Toxicology, University of Veterinary and Animal Sciences, Pakistan
2Department of Pharmacy, COMSATS University Islamabad, Pakistan
3Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Iran

Abstract

Introduction: Piroxicam has analgesic, anti-inflammatory and antipyretic activity. It inhibits the formation of prostaglandins, important regulator of the immune system. The current study was conducted to assess immunomodulatory effects of piroxicam on cell mediated as well as humoral immunity in mice.

Material and Method: Type 4 Delayed Hypersensitivity reaction (TDH) assay along with cyclophosphamide induced neutropenia were performed for the study of cell mediated immunity. The effect of the drug on humoral immunity was studied by the Hemagglutination Assay (HA) and mice lethality test. Mice were treated with piroxicam at a dose 5 mg/kg and 10 mg/kg intraperitoneally.

Result: The data was evaluated and analyzed via ANOVA (*P<0.05). There was significant reduction in mean skin thickness and neutrophil count in DTH assay and cyclophosphamide induced neutropenia respectively when compared to the control group. The dose dependent reduction was observed in HA assay. In mice lethality assay, the mortality ratio was higher in 10 mg/kg piroxicam treated group.

Conclusion: It is concluded from present study that piroxicam may have immunosuppressant effects addition to its analgesic action and it may be clinically effective in autoimmune diseases and organ transplantation.

Keywords: Piroxicam; Cell mediated immunity; Humoral immunity

Introduction

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are the most commonly used drugs world widely and they are as effective as opioids and acetaminophen in treating acute musculoskeletal pain [1,2]. Piroxicam is an oxicam derivative, a NSAID having analgesic, anti-inflammatory and antipyretic property that is generally used to mitigate many inflammatory diseases like rheumatoid arthritis, osteoarthritis, musculoskeletal disorders and postoperative pain [3,4]. In vitro, the potency of piroxicam as an inhibitor of Prostaglandin (PG) biosynthesis is similar to indomethacin. Piroxicam is a preferential Cyclooxygenase-1 (COX-1) inhibitor [2]. The drug inhibits the formation of prostaglandins which plays a vital role in immune system [5-7]. Piroxicam stimulates or modulates the immune functions requiring lymphoproliferation by suppressing the formation of PG-E2 that is a natural inhibitor of both LC (Lympho Proliferative Cytokines) and LC-induced lymphoproliferation [8,9].

Immune system plays an important role for fighting against various diseases. Regulation of immune response can help in the treatment and prevention of a number of diseases [9]. In the immune system, antigen presenting cells are dendritic; macrophages produced cytokines and Prostaglandins (PG). Cytokines and PGs regulate immune responses [10]. Immune system has two main components that are adaptive and innate immunity. Acquired immunity has been intensively studied. The roles and mechanisms of innate immunity responses might be different in all organisms that have both innate and adaptive immunity and also those that possess only innate immunity. On the other hand, invading pathogenic microorganisms use several strategies to inhibit the host immune system for their survival [11].
DTH is a protecting localized cell-mediated immune response mainly against intracellular pathogens. It is commonly used for research to find immune reactions and it is an important diagnostic test in commercial settings [12]. Hemaggulination is a process of agglutination in which antibodies are bind with Red Blood Cells (RBCs). RBCs act as an antigen and are very suitable targets due to their availability. It is commonly used assay for the determination of the antibodies titer in a serum, viral quantification and blood grouping [13]. To measure serological responses in experimental models that are vaccinated with different vaccines, commonly employed method is mice lethality test [14].

Materials and Methods

Chemicals

Piroxicam was provided by Pfizer pharmaceuticals and polyethylene glycol 600 (PEG used as vehicle) purchased from Applichem industry, acetone from Riedel-de-Haen, Dinitrochlorobenzenes (DNCB) from Lancaster, cyclophosphamide powder for injection (cyclomide) from Pharmedic laboratory Pvt. Ltd Lahore, water for injection from Elixir Laboratories Pvt. Ltd. Lahore, ether solvent from Den Norsken Eterfabrikk oslo-Norway, Phosphate Buffer Saline (PBS) from Oxoid limited Basingstoke Hampshire (England).

Organism and vaccine

Pasteurella multocida strain of bovine origin was obtained from Veterinary Research Institute (VRI) Lahore, Pakistan. Hemorrhagic Septicemia (HS) vaccine against Pasteurella multocida. Sheep Red Blood Cells (SRBCs) used as antigen.

Experimental animal

Swiss Albino mice having weight range 25 gm to 35 gm and aged 6 to 8 weeks were purchased from VRI. All the experimental protocols were approved from Animal Ethical Committee of UVAS. Mice were kept in transparent plastic cages with 12 h of dark-light cycle starting 8 am to 8 pm in the animal house of UVAS, Lahore. Animals were provided a saw dust bedding which was cleaned on every alternative day taking into consideration all possible hygienic parameters. Animals were provided with pathogen free standardized mice food along with water ad libitum.

Piroxicam treatment/selection of dose

In every experiment 15 mice were used and divided into three groups (A, B and C) consisting 5 mice in each group. The first group (group A) was used as a control group (received PEG intraperitoneally), the second group and the third group (B and C) received 5 mg/kg and 10 mg/kg of piroxicam subcutaneously respectively. Piroxicam treatment/selection of dose (0.2 ml) of DNCB 2% was applied on right side of the skin. Skin with application at 4 cm2 shaved area of the skin on left side of every mouse was followed by 0.1 mL of sensitizing dose of DNCB 2% in acetone,数字化 vernier scale was used to measure the thickness of mice skin (mm). On 8th day of experiment i.e. Day 6 after sensitization, a boosted dose (0.2 ml) of DNCB 2% was applied on right side of the skin. Skin thickness was measured (mm) after 24, 48 and 72 h, using digital vernier scale. In control group, acetone 0.1 mL excluding DNCB was incorporated on skin, serving as placebo during the test.

Cyclophosphamide induced neutropenia: Swiss albino mice were pre-treated with the piroxicam and solvent for ten days. On day 10th of experimental protocol, cyclophosphamide at a dose (200 mg/kg subcutaneously) produced neutropenia and was considered day zero. Each mouse heart was punctured to collect the blood and Total Leukocyte Count (TLC) along with Differential Leukocyte Count (DLC) was performed prior to administration of cyclophosphamide. On 13th day of the test (on 3rd day) after injection of cyclophosphamide, same procedure was repeated as performed on 10th day. The TLC and DLC of piroxicam treated groups were compared with the values of the control [16].

Assessment of humoral immune immunity

Hemaggulination assay (HA): Albino mice were weighed and divided into three groups (A to C), each group has 5 mice. Groups C and D were pretreated with piroxicam for 14 days and group A received vehicle. On 14th day, each mouse was immunized with 0.5 × 107 Sheep Red Blood Cells (SRBCs) intraperitoneally. The day of immunization was referred to as day 0. On 28th day, blood samples were collected from each mouse, centrifuged the blood sample at 5000 rpm, 4°C for 10 min and serum was separated properly. Round-bottom 96-well plates (microtiter plates) was preferred for this assay. In each well, 50 (μl) of Phosphate Buffer Saline (PBS) was added. In the first column of the plate, added 50 μl of sample (serum of mice). Mixed each well and transfer 50 μl to the next well on its right. Added 50 μl of 0.5% sheep red blood cell working solution to each well and mixed properly. Hemaggulination was determined by titrating serum dilutions with sheep’s red blood cells (0.025 × 108 cells). The highest dilution of serum show hemagglutination in the microtitre plates at room temperature for two hours without any disturbance. The highest dilution of serum show hemaggulination was expressed as HA titre [17].

Mice lethality test: All albino mice were divided into three groups (A to C), each having 5 mice. Group C and D were treated with 5 mg/kg and 10 mg/kg of piroxicam intraperitoneally respectively and group A received solvent. On the 7th and 17th day of the experiment, each mouse of all groups (A to C) was immunized with Hemorrhagic Septicemia vaccine (HS vaccine). On 21st day the mice were challenged subcutaneously with 0.2 ml of Pasteurella multocida culture containing 107 cells per ml. The animal was observed for a period of 72 h (24, 48 and 72 h after injecting of Pasteurella multocida) to detect any mortality in the inoculated mice. The mortality ratio was determined by using the following formula [18].

\[
\text{Mortality ratio} = \frac{\text{No. of animals dead}}{\text{Total no. of animals}}
\]

Statistical analysis: One-way Analysis of Variance (ANOVA) followed by multiple comparison test i.e. LSD (Least Significant Difference) was used for statistical evaluation. The values are expressed as mean ± SD and *P<0.05 value was considered significant.

Results

Delayed type hypersensitivity (DTH) assay

Cellular immune response was measured by DTH. The mean difference of skin thickness was highly reduced at dose of 10 mg/kg than 5 mg/kg of piroxicam, administered intraperitoneally in group B and group C when compared against control group A. There was significant difference between the values of all the groups on 24, 48 and 72 h at the significant level of *P<0.05 (Table 1).

Cyclophosphamide induced neutropenia assay

The required dose of cyclophosphamide to produce neutropenia
Tables and figures:

### Table 1: Effect of piroxicam on delayed type hypersensitivity assay.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Changes in skin thickness of control group</th>
<th>Changes in skin thickness of 5 mg group</th>
<th>Changes in skin thickness of 10 mg group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before challenging with DNCB</td>
<td>0.684 ± 0.025884</td>
<td>0.592 ± 0.0311</td>
<td>0.556 ± 0.0089</td>
</tr>
<tr>
<td>After 24 hrs</td>
<td>0.618 ± 0.021679</td>
<td>0.586 ± 0.03033</td>
<td>0.522 ± 0.0130**</td>
</tr>
<tr>
<td>After 48 hrs</td>
<td>0.6 ± 0.014142</td>
<td>0.544 ± 0.0378</td>
<td>0.502 ± 0.01643**</td>
</tr>
<tr>
<td>After 72 hrs</td>
<td>0.586 ± 0.016733</td>
<td>0.528 ± 0.0376</td>
<td>0.482 ± 0.0204**</td>
</tr>
</tbody>
</table>

### Table 2: Effect of piroxicam cyclophosphamide induced neutropenia.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Total leukocytes</th>
<th>Percentage reduction</th>
<th>Lymphocytes</th>
<th>Percentage reduction</th>
<th>Monocytes</th>
<th>Percentage reduction</th>
<th>Neutrophils</th>
<th>Percentage reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>Before treatment</td>
<td>44.86%</td>
<td>After treatment</td>
<td>44.86%</td>
<td>After treatment</td>
<td>44.86%</td>
<td>After treatment</td>
<td>44.86%</td>
</tr>
<tr>
<td>5 mg/kg</td>
<td>448 ± 533.66</td>
<td>47.8 ± 5.61</td>
<td>61.7 ± 2.54</td>
<td>47.0 ± 5.61</td>
<td>61.7 ± 2.54</td>
<td>47.0 ± 5.61</td>
<td>61.7 ± 2.54</td>
<td>47.0 ± 5.61</td>
</tr>
<tr>
<td>10 mg/kg</td>
<td>552 ± 529.06</td>
<td>38.16 ± 3.722</td>
<td>2.72 ± 2.54</td>
<td>38.16 ± 3.722</td>
<td>2.72 ± 2.54</td>
<td>38.16 ± 3.722</td>
<td>2.72 ± 2.54</td>
<td>38.16 ± 3.722</td>
</tr>
</tbody>
</table>

### Table 3: Effect of piroxicam on haemagglutination titre.

All values of piroxicam at 5 mg/kg and 10 mg/kg are expressed as HA titre ± standard deviation when compared with control. Table 3 represents Log2 value of HA titre.

Comparison of Log 2 values of HA titre of piroxicam treated groups against control group. Results are expressed as mean ± SD (n=5). Data were analyzed by one-way Analysis of Variance (ANOVA) followed by multiple comparison test that is LSD *p<0.05, **p<0.01 and ***p<0.001 when compared against control group.

### Mice lethality test

Table 4 represented the percentage mortality ratio of piroxicam treated groups against control group. There was significant increase in mortality rate in piroxicam group treated at dose 10 mg/kg (100%). Mortality rate was seen less in 5 mg/kg treated group (80%) when compared against control group (40%).

### Discussion

Non-Steroid Anti-Inflammatory Drugs (NSAIDs) show analgesic, anti-inflammatory and anti-pyretic effect by inhibiting Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) [6]. They also modulate a number of immunological responses and play a key role as antitumor in the host immunity [19]. NSAIDs also inhibit NF-κ B activation and thus suppress cancer cell proliferation due to stopping the expression of survival related gene products [20-22].

This study was conducted on Albino mice, divided into 3 groups to explore the effects of piroxicam on cellular and humoral immunity. Results of this study showed that in addition to effective reduced the inflammation, fever and pain etc., piroxicam also has immunosuppressive effect. Different experimental models including Delayed Type Hypersensitivity reaction (DTH), cyclophosphamide induced neutropenia, Hemagglutination Assay (HA) and mice lethality test were performed to evaluate the effect of piroxicam on cellular and humoral immune system by comparing treated groups with the control group.

DTH is an important for the indication of cell-mediated immunity in vivo. We determined the DTH responses against DNCB by using previous method with some modifications [14]. DNCB resulted in reduction of Total Leukocyte Count (TLC) in control group, 5 mg/kg piroxicam treated group and 10 mg/kg piroxicam treated group by 44.86%, 73.46% and 79.58% respectively. Neutrophils was reduced in control group, 5 mg/kg and 10 mg/kg piroxicam treated group to 29.65%, 28.52% and 25.46% respectively. Statistical analysis showed that there was significant difference in the TLC and DLC i.e. neutrophils and lymphocytes counts before and after cyclophosphamide administration in drug treated groups (at dose 10 mg/kg) significant decreased in TLC as well as in DLC than at dose 5 mg/kg. There was no prominent effect on monocytes when compared against control group. All values were significantly different from control group *p<0.05 (Table 2).
cause contact hypersensitivity is generally regarded as a cell mediated rather than antibody mediated immune response. Previously it has been known that when DNCB and other chemicals, of having same structure, were applied topically, they might bind with various skin proteins to form macromolecules (dinitrophenol complex). These macromolecules are affected by skin Langerhans cells, macrophages and dermal dendritic cells. These macromolecules are subsequently processed [23]. The sensitized T-lymphocytes are converted to lymphoblasts and secrete lymphokines, these lymphokines cause the infiltration of inflammatory cells to show the defensive response and attract more scavenger cells at the site of reaction. Thus sensitive cells are immobilized to promote defensive (inflammatory) reaction [24]. This immunosuppressive effect may be started from the raise in CD8+ T-Cell percentage which could be lead to the suppression in cellular immune response [25]. The results of DTH suggested that piroxicam may suppress the cell mediated immunity as shown by decrease in skin thickness of mice. Decrease in skin thickness of mice showed that piroxicam has a suppressive effect on lymphocytes and accessory cell types required for the expression of reaction. The mean skin thickness values in mice treated with 10 mg/kg was significantly (*P<0.05) lower than 5 mg/kg piroxicam treated when compared with control group. There was significant decrease in skin sensitivity at 24, 48 and 72 h. Results of DTH response resembles with results of a study conducted by [26].

In cyclophosphamide induced neutropenia, cyclophosphamide injection induced myelosuppression in mice. It belongs to nitrogen mustard subclass of alkylating agents and acts as an immunosuppressive agent and interferes in DNA synthesis by alkylation of DNA and prevents growth of tumor cells. At the same time it can inhibit the rapid cell division of the normal tissues, such as the hematopoietic system and neutropenia occurred [27]. Total Leukocyte Count (TLC) and Differential Leukocyte Count (DLC) were affected before and after administration of cyclophosphamide injection in piroxicam treated groups as well as in control group. However percentage reduction in TLC and DLC were significantly caused more suppression at dose 10 mg/kg of piroxicam (*P<0.05) than 5 mg/kg piroxicam when compared with the control group. Piroxicam has no prominent effect on monocytes in drug treated groups before and after of TLC and DLC. The most important component of first line of cellular defense against invading microbes is neutrophils or Polymorphonuclear leukocytes (PMNs). Circulating neutrophils are triggered towards the site of infection by chemicals released by host or invading pathogen. Neutrophils ingest the microbes by phagocytosis process [28]. The neutrophil is a critical effector cell in cellular as well as in humoral immunity and has important function in bacterial killing and phagocytosis [29]. Results of a previous study were in-line with the results of cyclophosphamide induced neutropenia assay performed in this research [30].

To evaluate the effect of piroxicam on humoral immunity, hemagglutination assay and mice lethality test were performed. In the hemagglutination test, interaction of B cells with the antigen is responsible for the secretion of antibodies and also causes differentiation and propagation into these cells. These antibodies bind with their specific antigens, neutralize them and facilitated them for their elimination by forming latex [31]. In mice, antibodies produced against sheep red blood cells after sensitization was determined by Hemagglutination Assay (HA). B lymphocytes are responsible for their production. Antibodies are the integral part of humoral immune system [32]. Piroxicam produced Hemagglutination titre (HA titre) but it was lower in mice treated at a dose 10 mg/kg than 5 mg/kg piroxicam treated group when compared with the control group. Agglutination occurs if antibodies are formed against antigen. Significant decreased in HA titre indicate that there was decreased production of IgG and IgM antibodies in the serum of mice against sheep Red Blood Cells (RBCs). In some plates latex was appeared as a button indicates that there was no any agglutination of sheep RBCs. Sharififar et al. [33] reported in their study that HA titre was markedly decreased at 3 doses of Achillea wilhelmsii that supports the results of HA of my study.

Mice lethality test is one of the important tests in world that are conducted to evaluate serological responses in animals immunized with vaccines. In mice lethality test, mice were immunized by Hemorrhagic Septicaemia (HS) against bacterial culture Pasteurella multocida to all experimental animals. Pasteurella multocida is an organism that is very pathogenic for the mice and act on the mice by causing infection in the airway of the mice [31]. Piroxicam caused significant reduction in mortality ratio (*P<0.05), showed 100% mortality at dose 10 mg/kg and 80% at dose 5 mg/kg while only 40% mortality was observed in control group. The results of present research showed that production of antibodies by B-lymphocytes of test animal against Pasteurella multocida was reduced at highest dose of piroxicam (10 mg/kg) than other dose of 5 mg/kg when compared against control group. Results of a previous study on methanolic extract of Moringa oleifera were in-line with the results of this research to assess humoral immune response [34].

Conclusion

The results of the present study showed that piroxicam has significant effects on both the cell mediated as well as on the humoral immunity and suppress these arms of immune system, which may add to its potential role as a immunosuppressant agent and thus may play important role in the treatment of autoimmune diseases and also help in organ transplantation.

Acknowledgment

The authors are thankful to members of Department of Pharmacology & Toxicology of University of Veterinary and Animal Sciences, Lahore for providing financial support to carry out the work. The authors are also thankful to Dr. Jawad Nazir, Assistant Professor of Department of Microbiology for his cooperation during this work.

References


